Mesenchymal stem cells (MSCs) have gained significant traction in the treatment of various musculoskeletal disorders. Therefore, understanding mesenchymal stem cell therapy is essential for modern orthopaedic practice. These cells possess unique properties like self-renewal and multilineage differentiation. However, clinical application must always remain evidence-based and aligned with local laws.

Clinical outcomes in orthopaedics depend heavily on disease pathophysiology. Specifically, practitioners use MSCs to treat osteoarthritis, cartilage defects, and nonunion fractures. Recent research indicates that MSCs modulate the local environment through paracrine signaling. This biological activity promotes tissue repair and reduces inflammation in damaged joints.

Guidelines for Mesenchymal Stem Cell Therapy in India

In India, the Indian Council of Medical Research (ICMR) updated the National Guidelines for Stem Cell Research in 2025. These rules mandate that practitioners conduct all stem cell interventions within a research or clinical trial framework. Furthermore, a 2026 Supreme Court advisory emphasized that MSCs are not currently \"Standard Care\" for most conditions. Consequently, surgeons must obtain approval from Institutional Ethics Committees before offering these treatments to patients.

Patient safety remains the top priority during clinical application. Doctors must ensure comprehensive informed consent and communicate clearly regarding the experimental nature of the therapy. Additionally, they should monitor patients for long-term adverse effects as part of rigorous clinical documentation to ensure regulatory compliance and ethical practice.

Frequently Asked Questions

Does Indian law consider mesenchymal stem cell therapy as standard care?

No, the 2026 advisory clarifies that it is not yet standard care. Surgeons must only utilize it within approved research protocols and registered clinical trials.

Which sources do surgeons typically use for MSCs?

Surgeons typically use bone marrow aspirate concentrate (BMAC), adipose-derived tissues, and umbilical cord-derived cells for these procedures.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

1. Dilogo IH et al. Clinical application of mesenchymal stem cells in orthopaedics and traumatology in daily practice. EFORT Open Rev. 2026 May 01. doi: 10.1530/EOR-2026-0056. PMID: 42065225.
2. Indian Council of Medical Research (ICMR). National Guidelines for Stem Cell Research 2025.
3. Ministry of Health and Family Welfare (MoHFW) / Supreme Court of India Advisory. Regulatory Framework for Stem Cell Interventions. 2026.